Corbus Pharmaceuticals to Host KOL Event at ESMO Congress 2025

Corbus Pharmaceuticals will host a KOL event at ESMO Congress 2025 to discuss dose optimization data from its Phase 1/2 clinical study of CRB-701. The event will feature insights from leading HNSCC experts and include data from over 100 participants with HNSCC, cervical, or metastatic urothelial tumors. The event will be held on October 19th at the Berlin Germany Marriott.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) will host a key opinion leader (KOL) event at the European Society for Medical Oncology (ESMO) Congress 2025 to discuss dose optimization data from its Phase 1/2 clinical study of CRB-701. The event will feature insights from leading experts in head and neck squamous cell carcinoma (HNSCC) and will include data from over 100 participants with HNSCC, cervical, or metastatic urothelial tumors. The event is scheduled to take place on October 19th at the Berlin Marriott, Germany.

The event will provide an opportunity for investors and financial professionals to gain insights into the clinical progress of CRB-701, a next-generation antibody drug conjugate (ADC) targeting Nectin-4. CRB-701 has received Fast Track designation from the FDA for the treatment of recurrent or metastatic HNSCC, following a similar designation for relapsed/refractory metastatic cervical cancer in December 2024 FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma^[1].

The ongoing Phase 1/2 clinical trial (NCT06265727) is evaluating the safety, pharmacokinetics, and efficacy of CRB-701 in patients with advanced solid tumors that express high levels of Nectin-4. Early data presented at the 2025 ASCO Annual Meeting indicated an emerging objective response rate (ORR) of 57% and a disease control rate of 86% in HNSCC patients FDA Grants Fast Track Designation to CRB-701 for Pretreated Recurrent or Metastatic HNSCC^[2]. The study is expected to enroll approximately 348 patients and is currently ongoing in the US and Europe.

The KOL event at ESMO Congress 2025 will present dose optimization data from part A and part B of the study, which include CRB-701 administered at various doses and in combination with anti-PD-1 therapy. The primary endpoint of the study is to determine the maximum tolerated dose (MTD) of CRB-701 in part A and the objective response rate (ORR) in parts B and C FDA Grants Fast Track Designation to CRB-701 for Pretreated Recurrent or Metastatic HNSCC^[2].

Investors and financial professionals are encouraged to attend the event to gain a deeper understanding of the clinical development and potential of CRB-701 in treating advanced solid tumors.

References
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma^[1] https://www.stocktitan.net/news/CRBP/fda-grants-fast-track-designation-to-corbus-pharmaceuticals-nectin-4-of4rxeui55ct.html
FDA Grants Fast Track Designation to CRB-701 for Pretreated Recurrent or Metastatic HNSCC^[2] https://www.onclive.com/view/fda-grants-fast-track-designation-to-crb-701-for-pretreated-recurrent-or-metastatic-hnscc